Dynavax is taking a hypothesis-driven approach to build on the principle of intratumoral activation of key mechanisms of innate immunity. CpG nanoparticles can be used to focus delivery to specific tumor-bearing organs, particularly the liver. Tumor antigens linked to these CpG nanoparticles can generate highly effective anti-tumor T cell responses, and are especially efficient when injected directly into the tumor itself. We are conducting multiple preclinical studies to identify complementary anti-tumor therapeutics that, in combination, will enhance the anti-tumor immune response resulting from focused delivery of SD-101 or DV281. To expand the range of innate immune activators, Dynavax is also developing a small-molecule agonist that activates innate immunity through two other Toll-like receptors, TLR7 and TLR8.